ArticleImmunology2021
CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.
Open access · hybridAbstract read
In one paragraph
Article in Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 108 citations in OpenAlex.
- Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.Cell reports. Medicine · 2026Trial
- Mathematical and Mouse Models Identify Regulatory T Cell Influx as A Key Determinant of Acquired Resistance to PD-1 Immunotherapy.Cancer research · 2026Article
- Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity.Cancer research · 2026Article
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- CCR8The Journal of allergy and clinical immunology · 2026Article
- Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R.Cell communication and signaling : CCS · 2026Article
- CCR8 orchestrates an immunosuppressive niche in the liver to promote Echinococcus multilocularis infection.PLoS neglected tropical diseases · 2026Article
- Fluorescence tracking Treg movement identifies anti-CCR8 and radiation as a therapeutic combination.iScience · 2026Article
- Regulatory T Cell Heterogeneity in the Steady State and Tumor.Immune network · 2026Review
- Review
- Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer.Frontiers in cell and developmental biology · 2026Review
- Prostaglandin EProceedings of the National Academy of Sciences of the United States of America · 2025Article
- TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8Oncoimmunology · 2025Article
- Integrating Mathematical and Mouse Models Identifies T Regulatory Cell Influx as A Key Determinant of Acquired Resistance to PD-1 Immunotherapy.bioRxiv : the preprint server for biology · 2025Article
- Regulatory T cells in the tumour microenvironment.Nature reviews. Cancer · 2025Review
- Bispecific targeting of 4-1BB and CCR8 boosts antitumor immunity via Ti-Treg depletion and CD8iScience · 2025Article
- TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.Cancer letters · 2025Article
- Emerging Immunotherapy Targets in Early Drug Development.International journal of molecular sciences · 2025Review
- CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype.Journal of experimental & clinical cancer research : CR · 2025Article
- Chemokines that govern T cell activity in tumors.Current opinion in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 4 countries.
Sarah K WhitesideDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0003-4354-4713
Francis M GrantImmunology Programme, Babraham Research Campus, Babraham Institute, Cambridge, UK.
David S GyoriDepartment of Physiology, Semmelweis University, Budapest, Hungary.
Alberto G ContiDepartment of Pathology, University of Cambridge, Cambridge, UK.
Charlotte J ImianowskiDepartment of Pathology, University of Cambridge, Cambridge, UK.
Paula KuoDepartment of Pathology, University of Cambridge, Cambridge, UK.
Rabab NasrallahImmunology Programme, Babraham Research Campus, Babraham Institute, Cambridge, UK.
Firas SadiyahDepartment of Pathology, University of Cambridge, Cambridge, UK.
Sergio A LiraMount Sinai School of Medicine, Immunology Institute, New York, NY, USA.
Frank TackeDepartment of Hepatology & Gastroenterology, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Charité Universitätsmedizin Berlin, Berlin, Germany.
Robert L EilDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Oliver T BurtonImmunology Programme, Babraham Research Campus, Babraham Institute, Cambridge, UK.
James DooleyImmunology Programme, Babraham Research Campus, Babraham Institute, Cambridge, UK.
Adrian ListonImmunology Programme, Babraham Research Campus, Babraham Institute, Cambridge, UK.
Klaus OkkenhaugDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-9432-4051
Jie YangDepartment of Pathology, University of Cambridge, Cambridge, UK.
Rahul RoychoudhuriDepartment of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-5392-1853
Babraham Institute · GBUniversity of Cambridge · GBCharité - Universitätsmedizin Berlin · DEMemorial Sloan Kettering Cancer Center · USMount Sinai Hospital · USSemmelweis University · HU
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MMechanisms associated with flares and remission in colitisR01DK110352 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LIRA, SERGIO A. · 2017 to 2025
$5.1MMolecular pathogenesis of intestinal serrated polypsR01CA161373 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LIRA, SERGIO A. · 2011 to 2020
$3.7MBiotechnology and Biological Sciences Research Council BB/N007794/1Biotechnology and Biological Sciences Research Council BBS/E/B/000C0427Biotechnology and Biological Sciences Research Council BBS/E/B/000C0428Cancer Research UK C52623/A22597Medical Research Council MR/S024468/1Medical Research Council MR/S024468/2NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA161373NIDDK NIH HHS R01 DK110352Wellcome TrustWellcome Trust/Royal Society 105663/Z/14/Z
Abstract
CD4
Indexed as
AdenocarcinomaAnimalsColorectal NeoplasmsForkhead Transcription FactorsHumansImmune ToleranceLymphocytes, Tumor-InfiltratingMelanomaMelanoma, ExperimentalMiceMice, Inbred C57BLMice, KnockoutReceptors, CCR8Skin NeoplasmsT-Lymphocytes, RegulatoryCcr8 protein, mouseForkhead Transcription FactorsFoxp3 protein, mouseReceptors, CCR8cancerCCR8CD4+ T cellsCD8+ T cellsFoxp3immunotherapyTreg
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.